Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 1.74
TROV's Cash-to-Debt is ranked lower than
53% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. TROV: 1.74 )
Ranked among companies with meaningful Cash-to-Debt only.
TROV' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.74  Med: 37.2 Max: No Debt
Current: 1.74
Equity-to-Asset 0.32
TROV's Equity-to-Asset is ranked lower than
69% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. TROV: 0.32 )
Ranked among companies with meaningful Equity-to-Asset only.
TROV' s Equity-to-Asset Range Over the Past 10 Years
Min: -4.07  Med: 0.49 Max: 0.75
Current: 0.32
-4.07
0.75
Piotroski F-Score: 2
Altman Z-Score: -8.90
Beneish M-Score: -3.23
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -11214.65
TROV's Operating Margin % is ranked lower than
98% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. TROV: -11214.65 )
Ranked among companies with meaningful Operating Margin % only.
TROV' s Operating Margin % Range Over the Past 10 Years
Min: -10537.01  Med: -4127.8 Max: -1077.56
Current: -11214.65
-10537.01
-1077.56
Net Margin % -10969.30
TROV's Net Margin % is ranked lower than
98% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. TROV: -10969.30 )
Ranked among companies with meaningful Net Margin % only.
TROV' s Net Margin % Range Over the Past 10 Years
Min: -10289.76  Med: -4560.23 Max: -867.83
Current: -10969.3
-10289.76
-867.83
ROE % -148.77
TROV's ROE % is ranked lower than
86% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. TROV: -148.77 )
Ranked among companies with meaningful ROE % only.
TROV' s ROE % Range Over the Past 10 Years
Min: -114.59  Med: -102.41 Max: -96.39
Current: -148.77
-114.59
-96.39
ROA % -76.77
TROV's ROA % is ranked lower than
80% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. TROV: -76.77 )
Ranked among companies with meaningful ROA % only.
TROV' s ROA % Range Over the Past 10 Years
Min: -1064.26  Med: -67.95 Max: -51.11
Current: -76.77
-1064.26
-51.11
ROC (Joel Greenblatt) % -924.70
TROV's ROC (Joel Greenblatt) % is ranked lower than
84% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. TROV: -924.70 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TROV' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -17351.61  Med: -2344.73 Max: -1231.85
Current: -924.7
-17351.61
-1231.85
3-Year Revenue Growth Rate -4.70
TROV's 3-Year Revenue Growth Rate is ranked lower than
72% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. TROV: -4.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TROV' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -29.3  Med: -21.9 Max: -4.7
Current: -4.7
-29.3
-4.7
3-Year EBITDA Growth Rate 23.40
TROV's 3-Year EBITDA Growth Rate is ranked higher than
79% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. TROV: 23.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TROV' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -2.9  Med: 12.8 Max: 51
Current: 23.4
-2.9
51
3-Year EPS without NRI Growth Rate 25.10
TROV's 3-Year EPS without NRI Growth Rate is ranked higher than
78% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. TROV: 25.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TROV' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -3.5  Med: 17.95 Max: 56.4
Current: 25.1
-3.5
56.4
GuruFocus has detected 3 Warning Signs with TrovaGene Inc $TROV.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TROV's 30-Y Financials

Financials (Next Earnings Date: 2017-08-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

TROV Guru Trades in Q3 2015

Jim Simons Sold Out
» More
Q4 2015

TROV Guru Trades in Q4 2015

First Eagle Investment 376,111 sh (New)
» More
Q1 2016

TROV Guru Trades in Q1 2016

First Eagle Investment Sold Out
» More
Q1 2017

TROV Guru Trades in Q1 2017

Jim Simons 29,124 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with TROV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621512    SIC: 8071
Compare:NAS:DRIO, NAS:BIOP, OTCPK:LXXGF, NAS:OPGN, OTCPK:TDSGF, NAS:CDNA, OTCPK:SQIDF, NAS:GENE, OTCPK:MYAN, NAS:CBMX, NAS:IDXG, OTCPK:MHTX, NAS:ROKA, OTCPK:ILIU, OTCPK:MNLIF, OTCPK:GNWSF, NAS:BASI, OTCPK:SEOVF, OTCPK:CRRVF, NAS:TEAR » details
Traded in other countries:XE7A.Germany,
Headquarter Location:USA
TrovaGene Inc is a molecular diagnostic company that focuses on the development and commercialization of a proprietary molecular diagnostic technology for use in disease detection and monitoring across a variety of medical disciplines.

TrovaGene Inc was incorporated in the State of Delaware on April 26, 2002 as Used Kar Parts, Inc. On July 2, 2004, the Company acquired Xenomics, a California corporation, which was developing and commercializing TrDNA technology. As part of the acquisition, its corporate name was changed to Xenomics, Inc. (Xenomics) The Company re-domesticated its state of incorporation from Florida to Delaware and its name was changed to Trovagene, Inc. It is a development stage molecular diagnostic company that focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. Its novel tests predominantly use transrenal DNA, or Tr-DNA, and transrenal RNA, or Tr-RNA. The Company is leveraging its proprietary urine-based molecular diagnostic technology for the detection of cell-free DNA and RNA originating from diseased cell death that can be isolated from urine and detected to improve disease management. These genetic materials are also collectively referred to as cell-free nucleic acids, which result when cells in the body die and release their DNA or RNA into the bloodstream. Its fundamental urine-based molecular diagnostic platform is protected by a intellectual property portfolio. The Company's developed intellectual property around cell-free nucleic acids in urine, the extraction of cell-free nucleic acids from urine, as well as novel assay designs, particularly its proprietary non-naturally occurring primers. As of February 28, 2014, its property portfolio consists of over 130 issued patents and over 47 pending patent applications. The Company faces direct competition in the area of transrenal cell-free DNA or RNA detection and analysis is precluded by its growing patent estate. Its competitors include medical diagnostic companies, of which have financial, technical, and marketing resources greater than its resources.

Ratios

vs
industry
vs
history
PB Ratio 1.88
TROV's PB Ratio is ranked higher than
81% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. TROV: 1.88 )
Ranked among companies with meaningful PB Ratio only.
TROV' s PB Ratio Range Over the Past 10 Years
Min: 1.9  Med: 5.74 Max: 70.71
Current: 1.88
1.9
70.71
PS Ratio 59.09
TROV's PS Ratio is ranked lower than
97% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. TROV: 59.09 )
Ranked among companies with meaningful PS Ratio only.
TROV' s PS Ratio Range Over the Past 10 Years
Min: 62.73  Med: 282.5 Max: 916.43
Current: 59.09
62.73
916.43
EV-to-EBIT -0.20
TROV's EV-to-EBIT is ranked lower than
99.99% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. TROV: -0.20 )
Ranked among companies with meaningful EV-to-EBIT only.
TROV' s EV-to-EBIT Range Over the Past 10 Years
Min: -27.2  Med: -5.95 Max: -0.2
Current: -0.2
-27.2
-0.2
EV-to-EBITDA -0.21
TROV's EV-to-EBITDA is ranked lower than
99.99% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. TROV: -0.21 )
Ranked among companies with meaningful EV-to-EBITDA only.
TROV' s EV-to-EBITDA Range Over the Past 10 Years
Min: -27.3  Med: -5.95 Max: -0.2
Current: -0.21
-27.3
-0.2
Current Ratio 3.32
TROV's Current Ratio is ranked higher than
77% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. TROV: 3.32 )
Ranked among companies with meaningful Current Ratio only.
TROV' s Current Ratio Range Over the Past 10 Years
Min: 0.46  Med: 8.15 Max: 20.57
Current: 3.32
0.46
20.57
Quick Ratio 3.32
TROV's Quick Ratio is ranked higher than
80% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. TROV: 3.32 )
Ranked among companies with meaningful Quick Ratio only.
TROV' s Quick Ratio Range Over the Past 10 Years
Min: 0.46  Med: 8.15 Max: 20.57
Current: 3.32
0.46
20.57
Days Sales Outstanding 82.25
TROV's Days Sales Outstanding is ranked lower than
76% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. TROV: 82.25 )
Ranked among companies with meaningful Days Sales Outstanding only.
TROV' s Days Sales Outstanding Range Over the Past 10 Years
Min: 74.3  Med: 111.33 Max: 140.06
Current: 82.25
74.3
140.06
Days Payable 173.45
TROV's Days Payable is ranked higher than
91% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. TROV: 173.45 )
Ranked among companies with meaningful Days Payable only.
TROV' s Days Payable Range Over the Past 10 Years
Min: 238.48  Med: 604.08 Max: 18201.33
Current: 173.45
238.48
18201.33

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.60
TROV's 3-Year Average Share Buyback Ratio is ranked lower than
70% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. TROV: -17.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TROV' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -38.2  Med: -22.55 Max: -17.6
Current: -17.6
-38.2
-17.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 3.61
TROV's Price-to-Net-Cash is ranked higher than
90% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.15 vs. TROV: 3.61 )
Ranked among companies with meaningful Price-to-Net-Cash only.
TROV' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.25  Med: 6.66 Max: 208.67
Current: 3.61
3.25
208.67
Price-to-Net-Current-Asset-Value 3.10
TROV's Price-to-Net-Current-Asset-Value is ranked higher than
88% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.79 vs. TROV: 3.10 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
TROV' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.21  Med: 6.51 Max: 156.5
Current: 3.1
3.21
156.5
Price-to-Tangible-Book 1.88
TROV's Price-to-Tangible-Book is ranked higher than
84% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.28 vs. TROV: 1.88 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
TROV' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.08  Med: 6.1 Max: 63.88
Current: 1.88
3.08
63.88
Price-to-Median-PS-Value 0.21
TROV's Price-to-Median-PS-Value is ranked higher than
91% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. TROV: 0.21 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TROV' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.37  Med: 1 Max: 2.54
Current: 0.21
0.37
2.54
Earnings Yield (Greenblatt) % -500.00
TROV's Earnings Yield (Greenblatt) % is ranked lower than
99.99% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. TROV: -500.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TROV' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1605.8  Med: 0 Max: 0
Current: -500
-1605.8
0

More Statistics

Revenue (TTM) (Mil) $0.36
EPS (TTM) $ -1.33
Beta0.67
Short Percentage of Float10.33%
52-Week Range $0.65 - 5.98
Shares Outstanding (Mil)30.97

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 0 1 1
EPS ($) -1.18 -0.83 -0.77
EPS without NRI ($) -1.18 -0.83 -0.77
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for TROV

Headlines

Articles On GuruFocus.com
Phase 1 Safety Study Supports Planned Development of PCM-075 in AML May 25 2017 
Trovagene to Present at the 7th Annual LD Micro Invitational Conference on June 7, 2017 in Los Angel May 23 2017 
Trovagene Announces First Quarter 2017 Company Highlights and Financial Results May 10 2017 
Trovagene to Announce First Quarter 2017 Financial Results and Host Conference Call on Wednesday, Ma Apr 26 2017 
Trovagene to Present at the Pioneers 2017 Joseph Gunnar Conference on May 2, 2017 in New York City Apr 25 2017 
Trovagene Announces the Addition of Dr. Sandra Silberman to its Clinical Advisory Board Apr 13 2017 
Why People Lose Money Investing And What You Can Do About It Jul 29 2015 

More From Other Websites
ETFs with exposure to TrovaGene, Inc. : May 25, 2017 May 25 2017
Phase 1 Safety Study Supports Planned Development of PCM-075 in AML May 25 2017
TrovaGene, Inc. :TROV-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017 May 24 2017
Trovagene to Present at the 7th Annual LD Micro Invitational Conference on June 7, 2017 in Los... May 23 2017
Edited Transcript of TROV earnings conference call or presentation 10-May-17 9:00pm GMT May 10 2017
Trovagene reports 1Q loss May 10 2017
Trovagene Announces First Quarter 2017 Company Highlights and Financial Results May 10 2017
Trovagene to Announce First Quarter 2017 Financial Results and Host Conference Call on Wednesday,... Apr 26 2017
Trovagene to Present at the Pioneers 2017 Joseph Gunnar Conference on May 2, 2017 in New York City Apr 25 2017
ETFs with exposure to TrovaGene, Inc. : April 20, 2017 Apr 20 2017
Trovagene Announces the Addition of Dr. Sandra Silberman to its Clinical Advisory Board Apr 13 2017
TrovaGene and NewLink Genetics Find Investors Optimistic About Products Mar 31 2017
Trovagene to Present at The MicroCap Conference on April 4, 2017 in New York City Mar 27 2017
TrovaGene, Inc. :TROV-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Mar 21 2017
Trovagene to Present at the Sidoti & Company Spring 2017 Convention Mar 21 2017
TrovaGene (TROV) Reports Wider-than-Expected Loss in Q4 Mar 16 2017
Edited Transcript of TROV earnings conference call or presentation 15-Mar-17 9:00pm GMT Mar 15 2017
Trovagene Reports Fourth Quarter and Year End 2016 Financial Results Mar 15 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)